Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC

NCT00806923 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00806923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00806923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2005
Completion date
February 28, 2011
Enrollment
1,044 (actual)
Sites
154

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer